Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1
Nutrients · 2023
DOI: 10.3390/nu15071632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Jankiben R Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Basic Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
As breast cancer cells transition from letrozole-sensitive to letrozole-resistant, they over-express epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), and human epidermal growth factor receptor 2 (HER2) while acquiring enhanced motility and epithelial-to-mesenchymal transition (EMT)-like characteristics that are attenuated and reversed by glyceollin treatment, respectively. Interestingly, glyceollin inhibits the proliferation and tumor progression of triple-negative breast cancer (TNBC) and estrogen-independent breast cancer cells; however, it is unlikely that a single phytochemical would effectively target aromatase-inhibitor (AI)-resistant metastatic breast cancer in the clinical setting. Since our previous report indicated that the combination of lapatinib and glyceollin induced apoptosis in hormone-dependent AI-resistant breast cancer cells, we hypothesized that combination therapy would also be beneficial for hormone independent letrozole-resistant breast cancer cells (LTLT-Ca) compared to AI-sensitive breast cancer cells (AC-1) by decreasing the expression of proteins associated with proliferation and cell cycle progression. While glyceollin + lapatinib treatment caused comparable inhibitory effects on the proliferation and migration in both cell lines, combination treatment selectively induced S and G2/M phase cell cycle arrest of the LTLT-Ca cells, which was mediated by decreased cyclin B1. This phenomenon may represent a unique opportunity to design novel combinatorial therapeutic approaches to target hormone-refractory breast tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Basic Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.
- Southern Regional Research Center, United States Department of Agriculture, Agricultural Research Service, 1100 Robert E. Lee Blvd., New Orleans, LA 70124, USA.
- Section of Hematology and Medical Oncology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
ORCID-Profile: Bipika Banjara, Matthew E Burow, Syreeta L Tilghman
Förderung
- NIMHD NIH HHS
- NIH HHS
- NIGMS NIH HHS
- United States Department of Education
- NIH
Zitieren
APA
Patel, J. R., Banjara, B., Ohemeng, A., Davidson, A. M., Boué, S. M., Burow, M. E., & Tilghman, S. L. (2023). Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. Nutrients. https://doi.org/10.3390/nu15071632
Vancouver
Patel JR, Banjara B, Ohemeng A, Davidson AM, Boué SM, Burow ME, et al. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. Nutrients. 2023. doi:10.3390/nu15071632
BibTeX
@article{Patel2023,
author = {Patel, Jankiben R and Banjara, Bipika and Ohemeng, Afia and Davidson, A Michael and Boué, Stephen M and Burow, Matthew E and Tilghman, Syreeta L},
title = {Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15071632}
}
EUVIMED